Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 11/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21294502 | 0.89 | ACSS2 (0.72) | ACSS2SMN1; SMN2TP53HCRTR1HCRTR2 | |
| SCHEMBL29433329 | 0.89 | ACSS2 (0.61) | ACSS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21294495 | 0.89 | ACSS2 (0.61) | ACSS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21294529 | 0.87 | ACSS2 (0.59) | ACSS2SMN1; SMN2TP53HCRTR1HCRTR2 | |
| SCHEMBL21294476 | 0.86 | ACSS2 (0.67) | ACSS2SMN1; SMN2TP53NPC1POLB | |
| SCHEMBL29433465 | 0.85 | ACSS2 (0.56) | ACSS2SMN1; SMN2TP53NPC1POLB | |
| SCHEMBL21294566 | 0.85 | ACSS2 (0.56) | ACSS2SMN1; SMN2TP53NPC1POLB | |
| SCHEMBL21294555 | 0.84 | ACSS2 (0.56) | ACSS2SMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL29433416 | 0.84 | ACSS2 (0.56) | ACSS2SMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL21294444 | 0.84 | ACSS2 (0.55) | ACSS2SMN1; SMN2TP53NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-111566092-B | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-3710430-B9 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2024-10-30 | — | — | EP | disclosed |
| EP-3710430-B1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2024-07-03 | — | — | EP | disclosed |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | METABOMED LTD. (IL) | 2020-12-01 | — | — | US | disclosed |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | METABOMED LTD. (IL) | 2020-12-01 | — | — | US | disclosed |
| WO-2020230136-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| CN-111566092-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ACSS2 1/4885SMN1; SMN2 4648/4885TP53 3897/4885 |
| US-10851064-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | ACSS2 1/4885SMN1; SMN2 4648/4885TP53 3897/4885 |
| US-20190263758-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ACSS2 1/4885SMN1; SMN2 4648/4885TP53 3897/4885 |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ACSS2 1/4885SMN1; SMN2 4648/4885TP53 3897/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | ACSS2 1/4885SMN1; SMN2 4648/4885TP53 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.